Compare FTLF & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | IMUX |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 152.6M |
| IPO Year | 2006 | 2013 |
| Metric | FTLF | IMUX |
|---|---|---|
| Price | $9.31 | $9.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $21.50 | ★ $45.00 |
| AVG Volume (30 Days) | 37.0K | ★ 2.5M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $21,744,000.00 | N/A |
| Revenue This Year | $45.76 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $14.91 | ★ N/A |
| Revenue Growth | ★ 11.52 | N/A |
| 52 Week Low | $8.67 | $0.51 |
| 52 Week High | $20.98 | $10.91 |
| Indicator | FTLF | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 89.55 |
| Support Level | $8.67 | $0.74 |
| Resistance Level | $15.34 | N/A |
| Average True Range (ATR) | 0.57 | 0.36 |
| MACD | 0.15 | 1.08 |
| Stochastic Oscillator | 45.45 | 91.80 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.